Anticancer effects of myricetin derivatives in non‐small cell lung cancer in vitro and in vivo

Li, Mengmeng; Zha, Genlan; Chen, Rujun; Chen, Xin; Sun, Qian; Jiang, Hao

doi:10.1002/prp2.905

Cited by 14 publications

(4 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To further validate the therapeutic effects of myricetin in patient samples, we attempted to generate CML patient-derived xenograft mouse model but was not successful. Nevertheless, our in vivo findings are supported by the recent studies demonstrating the potent anticancer efficacy in ovarian cancer and non-small lung cancer in mice without causing toxicity [23,24].…”

Section: Discussionsupporting

confidence: 78%

Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E

Cai¹,

Li²,

Li³

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

Although imatinib has revolutionized the treatment of chronic myeloid leukemia (CML), s develop resistance to imatinib when progress to blast phase and relapse. Myricetin, a flavonoid compound found in natural plants, has multiple biological functions. In this study, we show that myricetin demonstrated potent efficacy in imatinib-resistant CML CD34+ stem/progenitor cells with less toxicity in normal bone marrow. Myricetin is also active against imatinib-resistant CML bulk cells. The in vitro observations on the therapeutic effects of myricetin were translatable to in vivo imatinib-resistant CML xenograft mouse models. Mechanism studies showed that myricetin decreased the phosphorylation of eIF4E and Ak strain transforming, and the protein level of c-Myc and Cyclin D1. Rescue studies using eIF4E (S209D) and (S209A) confirmed that eIF4E phosphorylation inhibition was the mechanism of myricetin’s action in CML. Our results suggest that myricetin may be a potential lead for drug development to overcome imatinib resistance in CML.

show abstract

Section: Discussionsupporting

confidence: 78%

Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E

Cai¹,

Li²,

Li³

et al. 2022

Anti-Cancer Drugs

View full text Add to dashboard Cite

show abstract

“…Besides, number of apoptotic cells enhanced after S4-2-2 treatment. Furthermore, invasiveness of A549 cells was prevented and number of migrating cells was decreased after S4-2-2 treatment [102].…”

Section: Lung Cancermentioning

confidence: 94%

Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways

Rahmani

Almatroudi

Allemailem

et al. 2023

IJMS

View full text Add to dashboard Cite

Cancer is a major public health concern worldwide and main burden of the healthcare system. Regrettably, most of the currently used cancer treatment approaches such as targeted therapy, chemotherapy, radiotherapy and surgery usually cause adverse complications including hair loss, bone density loss, vomiting, anemia and other complications. However, to overcome these limitations, there is an urgent need to search for the alternative anticancer drugs with better efficacy as well as less adverse complications. Based on the scientific evidences, it is proven that naturally occurring antioxidants present in medicinal plants or their bioactive compounds might constitute a good therapeutic approach in diseases management including cancer. In this regard, myricetin, a polyhydroxy flavonol found in a several types of plants and its role in diseases management as anti-oxidant, anti-inflammatory and hepato-protective has been documented. Moreover, its role in cancer prevention has been noticed through modulation of angiogenesis, inflammation, cell cycle arrest and induction of apoptosis. Furthermore, myricetin plays a significant role in cancer prevention through the inhibition of inflammatory markers such as inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (Cox-2). Moreover, myricetin increases the chemotherapeutic potential of other anticancer drugs through modulation of cell signaling molecules activity. This review elaborates the information of myricetin role in cancer management through modulating of various cell-signaling molecules based on in vivo and in vitro studies. In addition, synergistic effect with currently used anticancer drugs and approaches to improve bioavailability are described. The evidences collected in this review will help different researchers to comprehend the information about its safety aspects, effective dose for different cancers and implication in clinical trials. Moreover, different challenges need to be focused on engineering different nanoformulations of myricetin to overcome the poor bioavailability, loading capacity, targeted delivery and premature release of this compound. Furthermore, some more derivatives of myricetin need to be synthesized to check their anticancer potential.

show abstract

“…In line with the proapoptotic effect exhibited by myricetin on many tumor cell lines [ 62 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 ], this compound has also induced apoptosis in endothelial cells through a reactive oxygen species (ROS)-dependent mechanism [ 67 ]. Despite the fact that in vivo studies in rodents support the chemopreventive role of myricetin in different cancer models [ 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 ], there is no current clinical evidence of its preventive activity in cancer, nor are there any active clinical trials using this compound. Additional in vitro studies suggest a synergistic effect of myricetin with traditional anticancer drugs [ 86 ].…”

Section: Plant-derived Compounds Constituent Of Diet With Antiangioge...mentioning

confidence: 99%

Antiangiogenic Phytochemicals Constituent of Diet as Promising Candidates for Chemoprevention of Cancer

et al. 2022

View full text Add to dashboard Cite

Despite the extensive knowledge on cancer nature acquired over the last years, the high incidence of this disease evidences a need for new approaches that complement the clinical intervention of tumors. Interestingly, many types of cancer are closely related to dietary habits associated with the Western lifestyle, such as low fruit and vegetable intake. Recent advances around the old-conceived term of chemoprevention highlight the important role of phytochemicals as good candidates for the prevention or treatment of cancer. The potential to inhibit angiogenesis exhibited by many natural compounds constituent of plant foods makes them especially interesting for their use as chemopreventive agents. Here, we review the antitumoral potential, with a focus on the antiangiogenic effects, of phenolic and polyphenolic compounds, such as quercetin or myricetin; terpenoids, such as ursolic acid or kahweol; and anthraquinones from Aloe vera, in different in vitro and in vivo assays, and the available clinical data. Although clinical trials have failed to assess the preventive role of many of these compounds, encouraging preclinical data support the efficacy of phytochemicals constituent of diet in the prevention and treatment of cancer, but a deeper understanding of their mechanisms of action and better designed clinical trials are urgently needed.

show abstract

Anticancer effects of myricetin derivatives in non‐small cell lung cancer in vitro and in vivo

Cited by 14 publications

References 37 publications

Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E

Myricetin is effective and selective in inhibiting imatinib-resistant chronic myeloid leukemia stem and differentiated cells through targeting eIF4E

Myricetin: A Significant Emphasis on Its Anticancer Potential via the Modulation of Inflammation and Signal Transduction Pathways

Antiangiogenic Phytochemicals Constituent of Diet as Promising Candidates for Chemoprevention of Cancer

Contact Info

Product

Resources

About